Kantum Pharma

Kantum is developing a specific AKI therapy to help critical care clinicians prevent hundreds of thousands of deaths from AKI. This targeted therapy will be supported by development of a novel diagnostic test for AKI. Kantum Bio is developing two programs in parallel: (1) Selective receptor antagonist-based therapeutics for AKI and (2) a UDP-G diagnostic test. Kantum’s lead therapeutic development candidate, KB-1801, will be developed for the prophylaxis and treatment of AKI secondary to cardiovascular intervention. Furthermore, KB-1801 has potential in cardiovascular accidents and other conditions associated with AKI in the ICU (e.g. sepsis, polytrauma, nephrotoxicity). The UDP-G diagnostic test will enable early diagnosis of patients at risk for AKI and may be leveraged to select patients and guide their treatment in clinical studies and, ultimately, in clinical practice.